Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myasthenia gravis.

Vern C Juel1, Janice M Massey

  • 1Division of Neurology, Box 3403, Duke University Medical Center, Durham, North Carolina, 27710, USA. vern.juel@duke.edu

Orphanet Journal of Rare Diseases
|November 8, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Muscle & nerve·2026
Same author

Characterizing Perinatal Treatment Patterns and Outcomes in Myasthenia Gravis.

Muscle & nerve·2025
Same author

Autoimmune Myasthenia Gravis.

Continuum (Minneapolis, Minn.)·2025
Same author

A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.

Annals of neurology·2025
Same author

Sensitivity of Repetitive Nerve Stimulation Performed in Early and Later Stages of Myasthenia Gravis.

Muscle & nerve·2025
Same author

COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.

Muscle & nerve·2025
Same journal

Patient-driven surveys of mucopolysaccharidoses revealed patient-reported outcomes in the Japan MPS patient and family group.

Orphanet journal of rare diseases·2026
Same journal

Mapping the landscape of treatable inborn errors of metabolism: a systematic gene-level evaluation based on the ICIMD classification.

Orphanet journal of rare diseases·2026
Same journal

Cognitive function in adult NF1 patients without other cognitive disorders: a cross-sectional study.

Orphanet journal of rare diseases·2026
Same journal

Real-world insights into neurodevelopmental outcomes amongst people with congenital hyperinsulinism.

Orphanet journal of rare diseases·2026
Same journal

Care of patients with Phenylketonuria (PKU) in Germany - a claims data analysis from 2013 to 2023.

Orphanet journal of rare diseases·2026
Same journal

A lifespan pooled analysis of 832 cases: characterizing the lifespan profile of clinical presentations and comorbidities in congenital pulmonary airway malformation.

Orphanet journal of rare diseases·2026
See all related articles

Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, causing fatigable muscle weakness. Diagnosis involves pharmacologic, electrophysiologic, and serologic tests, with favorable prognoses due to advanced treatments.

Area of Science:

  • Neurology
  • Immunology
  • Autoimmune Diseases

Background:

  • Myasthenia gravis (MG) is a rare autoimmune neuromuscular junction disorder with a prevalence of approximately 1 in 5,000.
  • It is characterized by fluctuating, fatigable muscle weakness, often initially presenting as ocular symptoms like ptosis and diplopia.

Purpose of the Study:

  • To provide a comprehensive overview of myasthenia gravis, including its pathophysiology, diagnostic approaches, differential diagnoses, and contemporary management strategies.
  • To highlight the favorable prognosis of MG with current medical advancements.

Main Methods:

  • Diagnosis is supported by pharmacologic testing (edrophonium chloride), electrophysiologic studies (repetitive nerve stimulation, single-fiber electromyography), and serologic tests for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies.

Related Experiment Videos

  • Differential diagnosis involves excluding conditions such as congenital myasthenic syndromes, Lambert Eaton syndrome, botulism, and other neuromuscular or neurological disorders.
  • Treatment strategies are individualized, encompassing symptomatic relief with cholinesterase inhibitors and immunomodulatory therapies like corticosteroids, azathioprine, cyclosporine, and mycophenolate mofetil.

    • Main Results:

    • MG results from an antibody-mediated immune attack on the postsynaptic membrane at the neuromuscular junction.
    • Diagnostic methods confirm a primary postsynaptic neuromuscular junction disorder.
    • Effective treatments and intensive care have led to significantly improved outcomes.

    Conclusions:

    • Contemporary diagnosis and management of myasthenia gravis have led to a favorable prognosis, with mortality rates below five percent and near-normal life expectancy.
    • Individualized treatment plans, including symptomatic and immunomodulatory therapies, are crucial for managing MG.
    • Advances in diagnostic testing, immunotherapy, and intensive care have dramatically improved patient outcomes and quality of life.